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Original Report 
Economical multi-site intradermal regimen with 
purified chick embryo cell vaccine (Rabipur) prevents 
rabies in people bitten by confirmed rabid animals 
S.N. Madhusudana,@) N. Prem Anand, and Ranjini Shamsundar(‘) 
Objective: To determine the efficacy of a cost-effective multi-site intradermal regimen with purified chick embryo 
cell vaccine (PCECV, Rabipur) in preventing rabies in people bitten by confirmed rabid dogs. 
Methods: Thirty-two people of different age groups who were severely bitten by confirmed rabid dogs were 
immunized with PCECV using the WHO recommended multi-site intradermal regimen of 0.1 mL of vaccine at eight 
sites on day 0, at four sites on day 7, and at one site each on days 28 and 90. In addition, passive immunization with 
human or equine rabies immunoglobulin was administered to 22 of these people before administering vaccine. They 
were followed for up to 3 years with periodic estimation of neutralizing antibody levels in their serum by mouse 
neutralization test (MNT). 
Results: There was an excellent immune response with more than protective titers (>0.5 IU/mL) on all days tested 
up to the end of the 3-year observation period. More significantly, protective titers were seen in all subjects by day 
7. Only minimal side effects were observed. All the patients were doing well at the end of the 3-year observation 
period, which is generally considered to be the maximum incubation period for rabies in humans. 
Conclusions: It can be concluded that this multi-site regimen with or without passive immunization has prevented 
the development of rabies encephalitis in these people bitten by confirmed rabid dogs. This should encourage more 
such studies, so that this cost-effective economical regimen with safe and potent cell culture vaccines can replace 
highly reactogenic neural tissue-derived Semple vaccine in developing countries such as India. 
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INTRODUCTION 
Rabies continues to be a serious public health problem 
in many Asian, African and South American countries. 
The worldwide incidence of human rabies is estimated 
to be around 60 000, with 30 000 human deaths reported 
from India alone.’ In India, the continuing stray dog 
menace and the non-availability of modern cell culture 
vaccines (CCVs) in government-run hospitals are the 
two main factors responsible for the situation.2 About 
0.5 million people undergo post-exposure vaccination; 
more than two-thirds receive sheep brain derived 
Semple vaccine, and less than one-third receive CCVS.~ 
Rabies post-exposure treatment with CCVs such as 
human diploid cell vaccine (HDCV), purified chick 
embryo cell vaccine (PCECV) or purified Vero cell 
rabies vaccine (PVRV) is very expensive if a regular 
intramuscular dosage schedule is followed. Because of 
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this, the majority of people bitten by rabid dogs prefer 
to take multiple doses of nerve tissue-derived Semple 
vaccine, which is administered free of charge in govern- 
ment hospitals and dispensaries. Apart from causing 
local reactions like induration and abscess formation in 
many vaccinees, this vaccine can also produce severe 
neurologic complications in as many as 1 in 5000 cases.3 
Another drawback of this vaccine is the poor patient 
compliance leading to inadequate immunization and 
vaccine failures. It may take several years to introduce 
safe and potent CCVs in government-run hospitals. 
Many of the educated class, who are aware of the 
dangers of Semple vaccine, opt for modern CCVs despite 
the fact the whole treatment procedure may be very 
costly. The total cost of treatment with these vaccines in 
many cases may be more than the monthly earnings of 
the majority of people bitten by street dogs.4 
In developing countries such as India, as modern 
CCVs are not administered free of cost, there is scope 
for the introduction of cost-effective intradermal (ID) 
regimens, which are now gaining increasing popularity 
in countries like Thailand.5 Presently, the WHO recom- 
mends a two-site regimen with PVRV and an eight-site 
regimen with PCECV and HDCV6 By the use of these 
economical regimens, up to 65% of vaccine can be saved 
in comparison to conventional intramuscular regimens. 
Several studies, from both India and elsewhere, have 
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consistently demonstrated good immunogenicity of two- 
site and eight-site ID regimens.5,7-9 The earlier studies 
reported from India have not addressed the efficacy 
of ID regimens in preventing rabies in patients truly 
exposed to rabies, though these studies have confirmed 
good humoral responses to these regimens.‘,‘” In this 
paper, for the first time from India we report the efficacy 
of a multi-site ID regimen in preventing rabies in patients 
who were severely bitten by confirmed rabid animals. 
MATERIALS AND METHODS 
Patients 
Thirty-two patients of various ages and of both sexes 
who were bitten by dogs attended the department of 
Neurovirology, National Institute of Mental Health and 
Neuroscience (NIMHANS), Bangalore (India) for expert 
post-exposure advice during the period from January 
1994 to December 1995. Among these, 14 were adult 
males, eight were adult females, and 10 were children 
aged between 7 and 13 years. The source of exposure 
comprised 12 dogs who had inflicted multiple bite in- 
juries. Among these, nine were stray dogs and three were 
pet dogs but unimmunized. Three dogs had bitten only 
one patient each, but the remaining nine had bitten two 
to four persons at the same time. Subsequently, these 
animals were killed and their brains were brought to 
this laboratory for confirmation of rabies. Eighteen 
patients had multiple transdermal bites, three children 
had severe lacerated wounds on their faces, five had 
lacerated wounds on their forearms, and the remaining 
had one or two transdermal bites on forearms or legs. 
Classification as per WHOl’ revealed that all of them 
had category III exposure. All of these patients were 
otherwise healthy and not on any medication, including 
immunosuppressive drugs. 
Diagnosis of rabies in dogs 
Rabies was confirmed in all the 12 dogs by direct 
immunofluorescence examination of brain, as per the 
standard procedure. l2 The conjugate used was obtained 
from the Central Research Institute, Kasauli, (India).The 
brains of all the dogs tested had florid distribution of viral 
antigen in all the areas of brain tested. Subsequently, the 
results were also confirmed by mouse inoculation test.‘” 
The incubation period of these strains in mice varied from 
as short as 7 days to a maximum of 12 days. 
Management of patients 
Adequate local wound toilet and a dose of tetanus 
toxoid had been administered to 24 of these patients 
immediately after the bite by the local medical practi- 
tioner. The remaining patients did not receive immediate 
local treatment. All of these had received a dose of 
tetanus toxoid before presenting to us. The wound was 
not sutured in any patient, although in six cases severe 
lacerated injury was present. Passive immunization 
was administered to 22 patients within 3 days after the 
bite. Among these, 10 received equine rabies immuno- 
globulin (ERIG, PasteurMerieuxConnaught, Leon, 
France) at a dose of 40 IU/kg body weight, and 12 
patients received human rabies immunoglobulin (HRIG, 
Behring, Marburg, Germany) at a dose of 20 IU/kg body 
weight. The remaining 10 patients did not receive serum 
therapy, as they were very poor and could not afford 
to purchase either ERIG or HRIG from the market. 
Before administering ERIG to these patients, serum 
sensitivity was tested as recommended by the manu- 
facturer, following the usual precautions, but none of our 
patients was found to be sensitive. As far as possible, the 
total calculated dose of hyperimmune serum was 
infiltrated in and around the wounds, and the remainder 
was given deep intramuscularly. All of these patients 
(parents in the case of children) were verbally told 
about the known efficacy and usefulness of the multi- 
site ID regimen, and written consent was obtained for 
both the ID regimen and testing of blood samples. All 
of these patients were then given 0.1 mL of PCECV 
(Rabipur, Hoechst India Ltd, Mumbai, India) batch 
numbers 255 and 265, with potencies of 7.6 IU/mL and 
7.8 IU/mL respectively, by NIH test (personal com- 
munication from Hoechst India Ltd) intradermally at 
eight sites on day 0, at four sites on day 7, and at one site 
on days 28 and 90. In most cases, we were able to adhere 
to the sites recommended by the WHO, i.e. one each 
over deltoids, suprascapular regions, lower quadrant 
of abdomen, and lateral aspects of legs or thighs, but 
in some we had to alter the sites, depending on the 
distribution of wounds around which hyperimmune 
serum was infiltrated. Antibiotics were prescribed to 12 
of these patients, as they had a lot of soft tissue damage. 
Estimation of neutralizing antibody titers 
The patient’s sera were titrated for rabies-neutralizing 
antibodies on days 0,7,28 and 90, and at l-, 2- and 3-year 
intervals by performing the standard mouse neutraliza- 
tion test as advocated by the WH0.r4 The challenge 
virus standard (CVS) was obtained from the Central 
Research Institute, Kasauli. The titers were expressed in 
IUlmL in comparison to a local reference preparation 
of rabies immunoglobulin (RIG) previously calibrated 
against the first WHO international reference RIG with 
59 IU/mL. 
Statistical analysis 
The differences in the antibody titers seen in the groups 
with and without passive immunization were analyzed by 
applying Student’s t-test. 
Follow-up of patients 
Since all of these patients were from Bangalore, they 
were regularly followed, with instructions to report to us 
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for collection of blood at regular intervals until the end 
of the third year post-vaccination. 
cases. Only two patients were prescribed mild analgesics 
or antipyretics. 
RESULTS Follow-up of cases 
Neutralizing antibody titers 
None of our patients had detectable levels of antibodies 
on day 0 before administration of vaccine. The titers of 
neutralizing antibodies from day 7 to the end of the 3- 
year follow-up period are shown in Table 1. It can be 
seen that more than protective titers (>0.5 IU/mL)ll 
were present in all these patients from day 7, with more 
than adequate titers on days 28 and 90. Protective titers 
persisted until the end of the 3-year observation period. 
Furthermore, there was no significant difference in the 
titers observed between the groups with or without 
passive immunization (Table 2). 
The patients were followed for 3 years. Most of the 
patients reported on their own on specified dates. 
Some had to be repeatedly contacted via telephone or 
personally. All of them were alive and doing well at the 
end of the observation period. 
DISCUSSION 
Vaccine tolerance and side effects 
All of the patients, including 10 children, tolerated 
multiple ID inoculations. The side effects observed were 
mostly insignificant, and comprised itching or pain at the 
inoculation sites, occasional induration and erythema, 
mild fever, and cervical adenopathy in one case. These 
effects disappeared spontaneously in the majority of 
The development of rabies in non-immunized people 
after a genuine exposure is reported to vary from 15% 
to 60%, depending on several factors, such as quantum 
of virus inoculated, nature of wound, proximity to brain 
and spinal cord, body surface area of the victim, and as 
yet unknown reasons.15J6 All of the patients in this study 
had severe bite wounds, often multiple, and in four cases 
over the face; in all cases, the diagnosis of rabies in the 
biting animal was confirmed. Therefore, we expect that, 
without adequate immunization, 60% of these, i.e 16 
people, might have developed rabies. The incubation 
period of rabies is also variable, depending on severity 
and site of exposure, quantum of virus inoculated, and 
probably as yet unidentified factors. However, it is well 
Table 1. Rabies neutralizing antibody titers at different time intervals after ID immunization with PCECV 
Rabies neutralizing antibody titers* (IlJlml) 
On days At the end of 
Patient group 7 28 90 1st year 2nd year 3rd year 
Adult males 1.8 8.5 7.5 4.2 0.8 
(n=l4) (0.9-3.2) (6.5-12.5) (5.6-9.8) (1.8-6.7 ) (X3.4) (0.5-1.5) 
Adult females 2.1 
(n=8 ) (1.2-3.6) (~:;-lo.*) (E-8.5) (:::-6.5) 
2..0 0.7 
(I .2-3.5) (0.8-1.2) 
Children ( 7-l 3 yrs) 2.4 
(n=lO) (1.6-4.5) 
(~:~-13.5) 8.9 5.3 1.8 0.9 
(4.5-11.6) (1.5-6.5) (0.9-2.5) (0.5-1.4) 
*Geometric mean titers with range in parentheses. 
Table 2. Comparison of neutralizing antibody titers in the first 
3 months between the groups with and groups without passive 
immunization 
Patient group 
Neutralizing antibody 
titers (/Ulmlja on days 
7 28 90 
Vaccine alone 7.8 
(n=lO) (A::-3.6) (96L3.5) (5.6-10.8) 
HRIG+Vaccine 2.1 9.4 
(n=12) (0.8-3.9) (6.5-13.6) &1.3) 
ERIG+Vaccine 1.9 9.2 7.2 
(n=lO) (1.041) (7.2-13.9) (5.3-10.9) 
“Geometric mean titers with range in parenthesis (P20.005) 
HRIG, Human rabies immunoglobulin. 
ERIC. Equine rabies immunoglobulin. 
established that the incubation period in severe class III 
exposures may range from as little as a few days to a 
maximum of 3-6 months.3 Since all of these patients had 
severe class III exposure, we would expect incubation 
period in these cases to be a few days to a few weeks, 
and in any case not more than 6 months. The patients in 
this study were followed up for 3 years, which is con- 
sidered to be the longest incubation period. At the end 
of this period, all of our patients were alive and doing 
well. They still had protective levels of antibodies at that 
time. Therefore, we believe that timely administration of 
vaccine by the ID route and passive immunization as per 
the recommended schedule has prevented the develop- 
ment of rabies in these patients. 
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The best indicator of protection following post- 
exposure immunization is the development of adequate 
titers of neutralizing antibodies.” The role of cell- 
mediated immunity following rabies vaccination is still 
not very clear. The most significant aspect of the present 
study is the development of protective levels of anti- 
bodies by day 7 in all patients. The levels of neutralizing 
antibody titer obtained on day 7 are likely to be due 
to response to vaccine alone, as the titers were similar 
in those patients who took only vaccine without passive 
immunization. It is very unlikely that passively admini- 
stered antibody would be still detectable on day 7. These 
patients had more than adequate titers throughout the 
study period, and the titers did not differ significantly 
between the groups with and without passive immuniza- 
tion. The multiple ID inoculation on different parts of 
the body did not in any way cause significant discomfort 
to these patients, except for slight pain at the inoculation 
sites. The side effects seen were mild, except in one 
patient who developed fever and enlargement of cervical 
lymph nodes. 
Earlier studies from Thailand’s had revealed the 
efficacy of the two-site ID regimen in preventing rabies 
in people bitten by confirmed rabid dogs. In one of our 
previous studies,‘” we have also shown the excellent 
immune response to this two-site ID regimen of PCEC 
vaccine. In another study, when we compared the titers 
obtained with two-site and eight-site regimens, sero- 
conversion on day 7 was only in 20% of cases with the 
two-site regimen, in contrast to 100% seen with the eight- 
site regimen, and the titers of neutralizing antibodies 
were significantly greater on all days tested with the 
eight-site regimen (data to be published). Therefore, 
this makes the eight-site regimen more advantageous. In 
addition, this eight-site regimen requires fewer visits to 
the doctor. In all, our previous studies confirmed the 
efficacy of ID regimens in generating good and sustained 
immune responses. This encouraged us to try this 
regimen on patients bitten by confirmed rabid animals. 
We feel that the successful results seen in this study 
should encourage more such studies, particularly in 
centers with facilities for antibody estimation in the 
vaccinees. Another aspect that needs attention is the 
non-availability of rabies hyperimmune serum in govern- 
ment centers and the inability of poor patients to pur- 
chase either ERIG or HRIG from the market. In such 
situations, administration of vaccine alone by this regimen 
is likely to produce protective titers of neutralizing anti- 
bodies within 7 days, which is life-saving in post-exposure 
cases, as demonstrated by the survival of 10 severely 
exposed patients in this study. 
Though several studies have consistently demon- 
strated the efficacy of ID regimens, some important 
factors should be considered before recommending it 
for general use. The WHO guidelines for the use of this 
regimen, such as proper ID technique and use of the 
reconstituted vaccine within 6-8 h, should be strictly 
followed. Patients who are on immunosuppressive 
therapy or antimalarial drugs like chlorquine should not 
be given ID regimens. There are reports of inadequate 
immune response with this regimen in patients who 
were on chloroquine prophylaxis.19 We also do not have 
data on the immune response to ID regimens in mal- 
nourished and elderly people. In any case, it is always 
advisable to monitor the neutralizing antibody levels in 
every patient who takes this regimen, until uniform 
results are obtained in the field conditions prevalent in 
developing countries. Of greater concern is the minimum 
potency requirements of CCVs for ID administration. 
Though the WHO has advocated a minimum potency of 
2.5 IU/dose for a five- or six-dose intramuscular schedule, 
this may not be adequate for ID administration in small 
quantities. The batches of vaccine used in this study had 
potencies of 7.6 IU/mL and 7.8 IU/mL. It is necessary 
for pre-exposure studies to be conducted with batches of 
vaccine with marginal potencies in order to establish the 
minimum antigenic content of vaccines that can be used 
for ID administration. A recent study by Khaplowd et 
a120 has shown that a potency of 5 IU/mL is required for 
safe ID administration. 
To conclude, this prospective study has confirmed 
the efficacy of a multi-site ID regimen with PCECV in 
preventing rabies in people bitten by confirmed rabid 
dogs. Though the study population is small, the results 
should encourage more such studies so that, in future, 
this cost-effective regimen can replace vaccination with 
highly reactogenic Semple vaccine, which is often respon- 
sible for severe side effects and vaccine failures. 
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